0001193125-24-105862.txt : 20240423 0001193125-24-105862.hdr.sgml : 20240423 20240423070054 ACCESSION NUMBER: 0001193125-24-105862 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240419 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240423 DATE AS OF CHANGE: 20240423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 24862664 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 8-K 1 d804228d8k.htm 8-K 8-K
false 0001609809 0001609809 2024-04-19 2024-04-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 19, 2024

 

 

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37465   27-4326290
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

101 Cambridgepark Drive  
Cambridge, MA   02140
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.001 per share   MCRB  

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 19, 2024, Seres Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”).

The letter has no immediate effect on the listing of the Common Stock on The Nasdaq Global Select Market, and the Common Stock will continue to trade on The Nasdaq Global Select Market under the symbol “MCRB,” subject to the Company’s compliance with the other continued listing requirements of The Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days from receipt of the letter, or until October 16, 2024, to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to October 16, 2024. There can be no assurance that the Company will be able to regain compliance or that Nasdaq will extend the compliance period.

If the Company does not regain compliance with the Bid Price Requirement by October 16, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company must submit an application to transfer the listing of the Common Stock to The Nasdaq Capital Market, which requires the Company to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the Bid Price Requirement. The Company would also need to pay an application fee to Nasdaq and to provide written notice of its intention to cure the deficiency during the additional compliance period. As part of its review process, Nasdaq will make a determination of whether it believes the Company will be able to cure this deficiency.

If the Company does not regain compliance within the applicable compliance period(s), the Company expects that Nasdaq will provide written notification to the Company that the Common Stock will be subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel.

The Company intends to monitor the closing bid price of the Common Stock and may, if appropriate, consider taking actions to regain compliance with the Bid Price Requirement, including, subject to approval of the Company’s Board of Directors and its stockholders, implementing a reverse stock split.

There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or will otherwise be in compliance with other applicable Nasdaq listing rules within the applicable compliance period(s), that the Company will be able to successfully implement a reverse stock split, or, if the Company receives a delisting determination and decides to appeal the delisting determination, that such appeal would be successful.

Forward-Looking Statements Disclaimer

This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the Company’s intent or ability to transfer the listing of its common stock to The Nasdaq Capital Market, regain compliance with any applicable Nasdaq listing requirements, implement a reverse stock split, or the timing of any of the foregoing. These forward-looking statements are based on the Company’s management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), on March 5, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking

statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SERES THERAPEUTICS, INC.
Date: April 23, 2024     By:  

/s/ Thomas J. DesRosier

      Name: Thomas J. DesRosier
      Title: Executive Vice President and Chief Legal Officer
 EX-101.SCH 2 mcrb-20240419.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 mcrb-20240419_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 mcrb-20240419_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 19, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001609809
Document Type 8-K
Document Period End Date Apr. 19, 2024
Entity Registrant Name SERES THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37465
Entity Tax Identification Number 27-4326290
Entity Address, Address Line One 101 Cambridgepark Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 945-9626
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol MCRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d804228d8k.htm mcrb-20240419.xsd mcrb-20240419_lab.xml mcrb-20240419_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d804228d8k.htm": { "nsprefix": "mcrb", "nsuri": "http://serestherapeutics.com/20240419", "dts": { "inline": { "local": [ "d804228d8k.htm" ] }, "schema": { "local": [ "mcrb-20240419.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "mcrb-20240419_lab.xml" ] }, "presentationLink": { "local": [ "mcrb-20240419_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-19_to_2024-04-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d804228d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-19_to_2024-04-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d804228d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://serestherapeutics.com//20240419/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-24-105862-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-105862-xbrl.zip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c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end XML 16 d804228d8k_htm.xml IDEA: XBRL DOCUMENT 0001609809 2024-04-19 2024-04-19 false 0001609809 8-K 2024-04-19 SERES THERAPEUTICS, INC. DE 001-37465 27-4326290 101 Cambridgepark Drive Cambridge MA 02140 (617) 945-9626 false false false false Common stock, par value $0.001 per share MCRB NASDAQ false